NCT07646054 · NOT YET RECRUITING
Digital Lifestyle Coaching for Alzheimer's Disease Prevention in APOE4 Carriers
This trial is testing whether a year-long digital lifestyle coaching program can improve blood-based markers linked to Alzheimer's risk. Twelve hundred participants will be randomly assigned to either 16 virtual coaching sessions or an education-only control group. Researchers will track plasma p-tau217 and other biological markers via finger-prick blood samples. This is a Phase NA behavioral trial — it is evaluating whether the approach works, not testing a drug.
You may qualify if
- Current 23andMe Research participant with APOE4 positivity genetic variant
- Age 60 to 80 at time of consent
- Have access to an Android or Apple iPhone smartphone device and able to download study apps
- Lives in the United States and able to send and receive US Mail
- Able and willing to perform a self-administered saliva test at screening*for organic outreach only.
- Able and willing to perform a self-administered finger prick blood collection at three time points throughout the study.
You're excluded if
- Non-English speaking
- Lives outside of the United States
- Currently taking or planning on taking GLP-1 medications (Exenatide, Liraglutide, Albiglutide, Dulaglutide, Semaglutide or Tirzepatide) within the next 12 months
- Established diagnosis of Mild Cognitive Impairment, Alzheimer's Disease or other Neurodegenerative Disease (Parkinson's Disease, Amyotrophic Lateral Sclerosis, Huntington's Disease, Multiple Sclerosis or Frontotemporal Dementia).
- Current or past Oura Ring user (any Oura Ring use in the last 12 months)
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-06-12